A civil lawsuit involving Nashville-based Parkhill Tax Advisory Group, Mark Bianchi, and Head Genetics is drawing heightened attention from investors and legal observers, as court filings allege that a tax-advantaged investment tied to an early-stage biotech company was marketed using misleading claims about development history, regulatory progress, and scientific readiness.
The case, filed by Solidaris Capital and Cirrus Investments, centers on a charitable-deduction investment structure known as Tech2head Recovery. According to the complaint, investors were introduced to the opportunity through intermediaries connected to Parkhill and Mark Bianchi and were led to believe that Head Genetics represented a mature biotechnology platform rather than a newly formed startup. Geoffrey Dietrich is the founder of Solidaris Capital.
Head Genetics and the Investment Narrative
Head Genetics, like Parkhill, is a Nashville-based firm that has promoted itself as developing a saliva-based concussion diagnostic product. The company’s marketing materials described the technology as a potentially transformative tool for detecting traumatic brain injuries, particularly in youth sports, collegiate athletics, and professional football.
Investors allege they were told the technology had been under development since 2013, suggesting nearly a decade of scientific work and regulatory preparation. Public records cited in the lawsuit, however, show that Head Genetics was incorporated in 2022. Plaintiffs argue that this discrepancy materially altered the risk profile of the investment. This investment opportunity was, according to the alleged complaint, promoted by Mark Bianchi and his Parkhill tax advisory firm.
The complaint states that the alleged development timeline was central to the decision to invest, as a ten-year runway would normally be associated with clinical trials, regulatory filings, and peer-reviewed validation.
Alleged Regulatory and Scientific Misrepresentations
According to the lawsuit, Head Genetics referenced “FDA-approved materials” in its marketing, language that plaintiffs say implied regulatory approval. Independent searches of FDA databases allegedly revealed no submissions, approvals, or clearances for a Head Genetics diagnostic device.
Court filings further allege that:
- No clinical trials associated with Head Genetics appear on ClinicalTrials.gov
- No peer-reviewed scientific publications support the company’s claims
- No disclosed academic or medical partnerships validate the technology
For investors, the absence of these elements is significant. In medical device and diagnostic markets, regulatory filings and clinical data are typically prerequisites for serious institutional investment.
One filing states that investors were presented with “a regulatory posture that does not appear to exist outside of promotional materials.”
Founder Backgrounds Raised Additional Questions
The lawsuit also challenges representations allegedly made about Head Genetics’ leadership. Co-founder Fabian Maclaren was described to investors as a seasoned biotech executive with a history of major commercial exits, including a claimed $500 million transaction. Plaintiffs allege that attempts to verify these claims through public records, transaction databases, and industry sources were unsuccessful.
The complaint does not dispute the branding and design experience of co-founder George Gallo but argues that marketing expertise was emphasized while regulatory and scientific experience was overstated or implied.
Parkhill Tax Advisory Group and Mark Bianchi Named in Case
The involvement of Parkhill Tax Advisory Group (parkhillus.com) and Mark Bianchi has drawn particular attention because the investment was structured as a tax-advantaged opportunity. Plaintiffs allege that the deal was presented not only as a biotech investment but also as a charitable-deduction strategy, increasing investor reliance on the accuracy of the underlying representations.
According to court documents, Mark Bianchi and Parkhill-related entities played a role in facilitating or introducing the investment to the plaintiffs. The lawsuit alleges that this role carried an obligation to ensure that claims about Head Genetics were accurate and verifiable.
Discovery efforts now focus on tracing investor funds through a network of related entities. Subpoenas have been issued to third-party firms and financial institutions as plaintiffs attempt to determine how capital was allocated and whether it supported legitimate research or product development.
Comparisons to Past Biotech Controversies
While the lawsuit does not allege wrongdoing on the scale of the Theranos scandal, some legal and financial analysts have noted similarities in the early warning signs. In both cases, investors were presented with ambitious diagnostic claims supported by confident narratives but lacking transparent scientific validation.
The comparison has gained attention following coverage in legal and financial media questioning whether Head Genetics followed a familiar pattern of prioritizing marketing and presentation over demonstrable progress.
Why the Case Matters for Investors
The lawsuit highlights recurring risks associated with tax-driven investment structures tied to early-stage biotech companies. Legal analysts note that such arrangements can magnify investor exposure when the underlying business fails to meet basic validation thresholds.
For investors researching Parkhill Tax Advisory Group, Mark Bianchi, or Head Genetics, the case underscores the importance of independently verifying:
- Company formation dates and claimed development timelines
- FDA submissions and regulatory status
- Clinical trial activity and scientific publications
- Founder track records and prior exits
- How tax benefits are calculated and sustained
The plaintiffs allege they relied on professional assurances and structured presentations that later appeared inconsistent with public records. All allegations remain unproven, and defendants will have the opportunity to respond in court.
Ongoing Litigation
The cases remain active in Texas and Illinois, with discovery ongoing. No regulatory enforcement actions or criminal charges have been announced. Legal proceedings are expected to continue as courts evaluate the factual record.
For now, the lawsuit has placed Parkhill, Mark Bianchi, and Head Genetics under a level of public scrutiny that many investors rely on when conducting due diligence. As additional filings emerge, the case is likely to remain relevant to anyone evaluating tax-advantaged investments connected to early-stage biotechnology ventures.
About Parkhill Tax Advisory Group
Parkhill Tax Advisory Group, sometimes referred to as Parkhill or Parkhill US, has presented itself as a boutique tax advisory firm offering advanced tax-planning strategies for high-net-worth individuals and sophisticated investors based in Nashville, TN. Based on marketing materials and deal presentations, Parkhill claimed expertise in complex structures, including charitable deduction strategies and alternative investment vehicles designed to generate tax advantages tied to private investments.
Parkhill Tax Advisory Group is now connected to active civil litigation involving the failed Tech2head Recovery investment linked to Head Genetics Inc. According to court filings, plaintiffs allege that Parkhill-associated entities and individuals played a role in introducing, structuring, or facilitating a tax-advantaged investment that was based on allegedly misleading claims about the underlying biotech company’s development timeline, regulatory status, and commercial readiness.
About Mark Bianchi
Mark Bianchi is identified in court filings and due-diligence materials as an investment intermediary involved in tax-advantaged and alternative investment structures, including the Tech2head Recovery offering tied to Head Genetics Inc. Public records and deal materials associate Bianchi with Nashville-area financial and tax-oriented ventures, including work connected to Parkhill Tax Advisory Group, where he has been described as playing a role in introducing or facilitating investment opportunities to prospective clients.
According to pending litigation, Bianchi is alleged to have acted as a connector between investors and complex tax-driven investment products. Plaintiffs in the Head Genetics lawsuit allege that Bianchi’s involvement lent credibility to representations made about the underlying investment, including claims regarding development timelines, regulatory readiness, and the financial structure of the deal. These allegations remain unproven, and Bianchi is entitled to respond through the legal process.
Separate due diligence research cited by investors raises additional questions about Bianchi’s professional history, including prior tax-related disputes, regulatory scrutiny, and legal actions related to other financial or advisory activities. While not all matters resulted in formal findings of wrongdoing, analysts reviewing the Head Genetics transaction have noted a pattern of controversial or high-risk tax strategies associated with Bianchi’s prior business dealings. As a result, his role has become a focal point for investors conducting background checks related to the Parkhill and Head Genetics litigation.
This article is based on publicly available court filings, regulatory records, and prior reporting. All statements regarding misconduct are allegations made in civil litigation and remain unproven. Defendants are entitled to respond and to due process. This content is provided for informational purposes only and does not constitute legal or investment advice.